Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada

Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada

Background: Heart failure (HF) with reduced ejection fraction represents approximately 50% of the 600,000 Canadians currently living with HF and over 90,000 new cases diagnosed each year. The angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, demonstrated superior efficacy in reducing...

Full description

Bibliographic Details
Main Authors: Ashlay A. Huitema, MD, FRCPC, Alexia Daoust, MSc, Kim Anderson, MD, MSc, FRCPC, Stephanie Poon, MD, MSc, FRCPC, Sean Virani, MD, MSc, MPH, FRCPC, FCCS, Michel White, MD, FRCP(C), FACC, FESC, Carlos Rojas-Fernandez, PharmD, Shelley Zieroth, MD, FCCS, FRCPC, Robert S. McKelvie, MD, PhD, FRCPC
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:CJC Open
Online Access:http://www.sciencedirect.com/science/article/pii/S2589790X20300391

Internet

http://www.sciencedirect.com/science/article/pii/S2589790X20300391

Similar Items